+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: new insight into CXCR4-FC131 interactions

Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: new insight into CXCR4-FC131 interactions

Bioorganic and Medicinal Chemistry Letters 22(6): 2146-2150

CXCR4 is a G-protein coupled receptor that is associated with many diseases such as breast cancer metastasis, HIV infection, leukemic disease and rheumatoid arthritis, and is thus considered an attractive drug target. Previously, we identified a cyclic pentapeptide, FC131, that is a potent antagonist for CXCR4. In this study, we constructed a three dimensional model of the CXCR4-FC131 complex. To investigate the backbone flexibility of FC131, we performed molecular dynamics simulations of FC131 based on the NMR structure of FC131, and obtained snapshot structures from the trajectories which were used to model the docking pose of FC131 into CXCR4. Our final model of the CXCR4-FC131 complex is partially different from the X-ray crystal structure of CXCR4-CVX15 and suggests water-mediated interactions. Nevertheless, this docking pose is consistent with the experimental data. We believe our model will aid in the discovery and development of small-molecule antagonists for CXCR4.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 036335104

Download citation: RISBibTeXText

PMID: 22365757

DOI: 10.1016/j.bmcl.2012.01.134

Related references

Design and synthesis of all diastereomers of cyclic pseudo-dipeptides as mimics of cyclic CXCR4 pentapeptide antagonists. Organic and Biomolecular Chemistry 5(12): 1915-1923, 2007

Development of low molecular weight CXCR4 antagonists by exploratory structural tuning of cyclic tetra- and pentapeptide-scaffolds towards the treatment of HIV infection, cancer metastasis and rheumatoid arthritis. Current Medicinal Chemistry 14(1): 93-102, 2007

Development of Low Molecular Weight Cxcr4 Antagonists by Exploratory Structural Tuning of Cyclic Tetra- and Pentapeptide-Scaffolds Towards the Treatment of Hiv Infection, Cancer Metastasis and Rheumatoid Arthritis. Current Medicinal Chemistry 14(1): 93-102, 2007

Structure-activity relationship studies on CXCR4 antagonists having cyclic pentapeptide scaffolds. Organic and Biomolecular Chemistry 3(24): 4392-4394, 2005

Structure-activity relationship study of CXCR4 antagonists bearing the cyclic pentapeptide scaffold: identification of the new pharmacophore. Organic and Biomolecular Chemistry 6(23): 4374-4377, 2008

Development of novel CXC chemokine receptor 7 (CXCR7) ligands: selectivity switch from CXCR4 antagonists with a cyclic pentapeptide scaffold. Journal of Medicinal Chemistry 58(13): 5218-5225, 2015

A simple, automated quasi-4D-QSAR, quasi-multi way PLS approach to develop highly predictive QSAR models for highly flexible CXCR4 inhibitor cyclic pentapeptide ligands using scripted common molecular modeling tools. QSAR and Combinatorial Science 24(5): 620-630, 2005

Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds. Journal of Medicinal Chemistry 48(9): 3280-3289, 2005

Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. Journal of Biological Chemistry 276(17): 14153-14160, 2001

Tetrahydroisoquinoline CXCR4 Antagonists Adopt a Hybrid Binding Mode within the Peptide Subpocket of the CXCR4 Receptor. Acs Medicinal Chemistry Letters 10(1): 67-73, 2019

Pan-histone deacetylase (HDAC) inhibitor LBH589 depletes CXCR4 levels combination with CXCR4 antagonists.. 2007

Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists. Bmc Cancer 16: 305, 2017

Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers. Pharmacology and Therapeutics 128(3): 509-518, 2011

Pharmacological evidence for complex and multiple site interaction of CXCR4 with SDF-1alpha: implications for development of selective CXCR4 antagonists. Immunology Letters 78(1): 29-34, 2001

Small molecule CXCR4 antagonists block the HIV-1 Nef/CXCR4 axis and selectively initiate the apoptotic program in breast cancer cells. Oncotarget 9(24): 16996-17013, 2018